#Taiwan #Milan #Global Supply Chain #CPHI 2026 #Taiwan Pharma

Taiwan's Remarkable Showcase at CPHI Milan 2026

In the heart of Milan, the Taiwan Pharma Pavilion stood out at CPHI Milan 2026 as a beacon of innovation amid the evolving landscape of global pharmaceutical supply chains. Drug manufacturers worldwide are currently navigating a landscape characterized by rapid restructuring, emphasizing supply reliability, high-quality manufacturing, and diversified partnerships. Responding to these industry demands, Taiwan organized a powerful presentation featuring twenty-two leading biotech and pharmaceutical companies, all unified under the strategic support of the Taiwan Ministry of Economic Affairs (MOEA) and orchestrated by the Industrial Technology Research Institute (ITRI).

Taiwan has carved a reputation as a reliable partner within the international pharmaceutical ecosystem. This is evident from the robust foundation built by continuous investments in manufacturing efficiencies and novel drug developments. Currently, over 170 pharmaceutical manufacturers in Taiwan adhere to strict PIC/S GMP standards, demonstrating their commitment to quality and compliance. Remarkably, Taiwan exports more than 90% of its active pharmaceutical ingredients (APIs), and its finished pharmaceutical products successfully penetrate highly regulated markets, such as Japan and the United States, confirming its capacity for high-quality, scalable production.

Dr. Maggie Lu, the Vice President and General Director of Biomedical Technology and Device Research Laboratories at ITRI, remarked, "The global pharmaceutical supply chain is undergoing a strategic realignment. Pharmaceutical companies are increasingly seeking partnerships that transcend traditional manufacturing capabilities. Key criteria now include quality certifications, supply chain resilience, advanced research and development capabilities, and manufacturing flexibility. Taiwan's strengths in these areas position its pharmaceutical sector to play a more significant role on the global stage."

The Taiwan Pharma Pavilion distinguishes itself by shifting the focus from mere competitive volume to collaborative opportunities. This approach centers around three critical areas:

1. AI-Driven Drug Discovery & Preclinical Research: Leveraging Taiwan's significant prowess in Information and Communication Technology (ICT), the companies participating in the pavilion presented advanced AI platforms and research and development tools aimed at streamlining target identification, drug screening, and preclinical validation processes. This innovation could redefine the future of drug development, enabling faster and more efficient pathways to market.

2. APIs & CDMO Services: Taiwanese manufacturers have risen to the industry's demand for supply chain diversification. With a commitment to delivering reliable raw material supplies, scalable process development, and flexible contract manufacturing services, these companies back such commitments with international certifications, making them indispensable components of the global supply chain.

3. Innovative Therapeutics & Advanced Formulations: Taiwan illustrates its cutting-edge capabilities in creating novel drugs, high-barrier generics, and sophisticated drug delivery technologies, fostering avenues for co-development, technology licensing, and markets expansion on a global scale.

Taiwan's presence at CPHI Milan extends well beyond the exhibition floor, reaching executive levels of influence. Dr. Maggie Lu's invitation to deliver opening remarks at the highly regarded CPHI Leadership Summit highlights the region's growing importance within the global landscape. This high-profile platform grants Taiwan an opportunity to directly engage with senior executives from pharmaceutical leaders, including Boehringer Ingelheim, FUJIFILM, and Lonza, situating Taiwan's integrated strengths within influential strategic discussions about the future trajectory of the pharmaceutical industry.

In sum, Taiwan’s “Team Taiwan” approach seamlessly combines the entire pharmaceutical value chain, from pioneering AI-driven drug discovery to commercial-scale manufacturing capabilities. By enhancing partnerships in raw material supply, contract manufacturing, co-development, and global licensing, Taiwan stands ready to assume a crucial role in shaping the future of global healthcare, facilitating advancements that promise improved therapeutic options for the global population.

Taiwan's example at CPHI Milan 2026 serves as a testament to its commitment to fostering innovation, quality, and reliability within the international pharmaceutical community, aligning with the industry's shift toward integrated and resilient solutions for current and future challenges.